Allow time for scheduling.
Furthermore, our studies have also explored the rationale for sequence scheduling when MEK inhibitors and agents targeting mitosis are combined.
Here, we identify cells in G2 that are capable of escaping topoisomerase I inhibition, with major implications for the design rationale for the scheduling of topotecan anticancer therapy.
The rationale for the scheduling of MSC and GCV administration is based on the investigators preclinical studies, where these time intervals have proven optimal for ensuring that MSCs have enough time to enter the tumor stroma from the peripheral circulation and activate the therapeutic transgene [9, 10, 11, and unpublished data].
These observations established the rationale for the schedule-dependency and likely antitumor activity, and formed the basis for the design of the first Phase I dose escalation study.
As a consequence of this slower proliferation, these tumours respond in a similar manner to late-responding normal tissue rather than early responding normal tissue [13 15], thereby removing the rationale for hyperfractionated schedules.
The rationale for this schedule was that the vascular effect of the VDA would cause 'trapping' of the already present cytotoxic drug within the tumour, and, at the same time, that the possible VDA-induced impairment of PTX distribution in the tumour would be avoided (Chaplin et al, 2006).
Previous experimental studies indicated a rationale for repetitive RTX scheduling based on B-cell kinetics [ 5, 6, 16], but variable time lag between B-cell repopulation and clinical flare limited the immediate clinical application of B-cell repletion monitoring.
In various clinical settings the ability to follow the apoptotic process in patient samples may offer the rationale for optimal treatment schedules.
This work provided a rationale for improving the schedule of administration of S9788 in clinical trials.
